A Difficile Challenge: The Impact of New
Clinical Outcomes and Economics in C. Difficile Infection
A continuing medical education activity sponsored by NAMCP and AAMCN.
This activity is an archive from the
live webinars held on March 20, 2018 and April 10, 2018. If you
participated in the live session, you are not eligible for
continuing education credits from this archive.
This activity is valid from May 20, 2018 to May 31, 2019
Instructions for CME/CNE: Complete the pre-test, listen to the audio
and view the slides, complete the post test, complete the evaluation
form and hit submit. You will be asked to enter your name and email
address on the pre-test, evaluation and post-test. If you close your
internet browser without completing the post test, you will have ONE
more opportunity to complete. A score of 70% must be achieved on the
post test to receive continuing education credits. If you do not
pass the post test after two attempts, you will not be eligible to
try again. Once you complete the evaluation form and score 70% or
higher on your post test, you will automatically be given your
To print or save your certificate, you will need to click on the
“download” button and either print or save.
Audience: This activity is intended for
healthcare professionals practicing in managed care environments.
This presentation is supported by an
educational grant from
Merck & Co
Clostridium difficile, a Gram-positive bacteria that causes
diarrhea, abdominal bloating, and colitis, is associated with
significant morbidity and mortality. Up to 25% of patients with an
initial episode of C. difficile infection (CDI) experience disease
recurrence. Recurrent CDI is particularly challenging to manage.
Although a number of therapies with varying mechanisms of action are
available to treat CDI and prevent recurrence, the management of CDI
is complex and challenging. This webinar will provide attendees with
up-to-date knowledge of evidence-based treatment and management
strategies of initial and recurrent CDI to improve clinical and
Upon Completion of this
activity, participants will be able to:
Analyze the recently updated IDSA
and SHEA clinical practice guidelines for the management of CDI
Discuss how changes to the clinical
practice guidelines will change management in CDI
Examine therapeutic agents and
regimens that reduce the occurrence of antimicrobial resistance
and improve outcomes for patients with CDI
Analyze the clinical efficacy and
safety of biologics for prevention of recurrent CDI
Identify patients at risk for CDI
based on history, presentation, and the appropriate risk
||Ciarán P. Kelly, MD
Professor of Medicine
Harvard Medical School
Director, Gastroenterology Fellowship Training
Medical Director, Celiac Center
Beth Israel Deaconess Medical Center
serves as a consultant and/or on an advisory board for
Biocodex, Merck, Seres Therapeutics, Summit, and
Synthetic Biologies. He received grant/research support
from the Institut Merieux, Merck, and the National
Institutes of Health. His presentation has been peer
reviewed for any bias.
MD has no relevant financial relationships to disclose.
Jeremy Williams has no relevant financial relationships
Jacqueline Cole, RN, MS, CMCN has no relevant financial
relationships to disclose.
NAMCP and/or the presenter
has copyright or has received permissions for use of
materials provided in this activity.
Accreditation & Designation
The National Association of Managed Care Physicians (NAMCP) is
accredited by the Accreditation Council for Continuing Medical
Education to provide continuing medical education for physicians.
NAMCP designates this enduring material for a maximum of 1 AMA
PRA Category I creditsTM.
The American Association of Managed Care Nurses is accredited as a
provider of continuing nursing
education by the American Nurses Credentialing Center’s Commission
Nurses who complete this activity and achieve a passing score will
receive 1 hour in continuing
This activity has been approved by the American Board of Managed
Care Nursing for 1.0 contact hours toward CMCN recertification
supported by an educational grant from
Merck & Co
NAMCP and/or this website does not
provide medical advice, diagnosis or treatment. NAMCP does not
endorse or imply endorsement of the content on any linked website.
This website is to be used as an informational resource. With any
health related concern, consult with your physician or healthcare
Click Here To Continue